|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.3 GBX | +2.26% |
|
-0.54% | -10.37% |
| 07-02 | Alliance Pharma plc Announces Termination of Mr. Peter Jonathan Butterfield as Director | CI |
| 06-19 | Alliance Pharma pays no dividend as board focus on reinvesting cash | AN |
Alliance Pharma plc announced unaudited revenue results for the year ended December 31, 2022. The Group delivered see-through revenues of £172.0 million in the Year (2021: £169.6 million), in line with the trading update on 23 November 2022 and up 1% on the prior year. Adjusting for currency, revenues declined 3%.
Excluding sales from ScarAway™ and the US rights to Kelo-cote™, both acquired in March 2022, like-for-like2 see-through revenues declined 6% at constant exchange rates.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.37% | 250M | |
| +26.58% | 45.33B | |
| +38.49% | 25.36B | |
| +27.83% | 16.7B | |
| +20.89% | 14.59B | |
| +72.03% | 14.26B | |
| -0.05% | 6.79B | |
| -10.35% | 6.67B | |
| +13.07% | 5.62B | |
| -8.87% | 5.73B |
ALLIANCE PHARMA PLC 